Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.
about
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress DisordersAntidepressants for generalised anxiety disorder (GAD)Antidepressants for generalised anxiety disorder (GAD)The noradrenergic paradox: implications in the management of depression and anxietyCanadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersA psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care.Psychopharmacology of anxiety disorders.Anxiety and Depression: Optimizing Treatments.Generalized anxiety disorder: acute and chronic treatment.Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology.Pharmacological treatment for generalized anxiety disorder in adults: an update.Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention.Serotonin noradrenaline reuptake inhibitors: A new generation of treatment for anxiety disorders.Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trialSNRIs: mechanism of action and clinical features.Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label studyA Review of the Diagnosis, Pharmacologic Treatment, and Economic Aspects of Anxiety Disorders.Comorbidities in chronic neuropathic pain.Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobiaParoxetine in the treatment of generalised anxiety disorder.Venlafaxine in the treatment of anxiety disorders.Treatments for generalized anxiety disorder.Escitalopram in the treatment of generalized anxiety disorder.A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorderTreatment of anxiety disorders with venlafaxine XR.The diagnosis and treatment of generalized anxiety disorder.INFLUENCE OF STUDY DESIGN ON TREATMENT RESPONSE IN ANXIETY DISORDER CLINICAL TRIALSThe role of duloxetine in the treatment of anxiety disorders.Ramelteon for insomnia symptoms in a community sample of adults with generalized anxiety disorder: an open label study.Attention modification program in individuals with generalized anxiety disorderPost Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone.Venlafaxine in the treatment of panic disorderRedefining affective disorders: relevance for drug development.Establishing non-inferiority in treatment trials in psychiatry: guidelines from an Expert Consensus Meeting.A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder.Duloxetine for the treatment of generalized anxiety disorder: a review.Selective serotonin reuptake inhibitors in the treatment of generalized anxiety disorder.The effects of venlafaxine and cognitive behavioral therapy alone and combined in the treatment of co-morbid alcohol use-anxiety disorders.Evidence-based review of clinical outcomes of guideline-recommended pharmacotherapies for generalized anxiety disorder.
P2860
Q22305681-CCCBE9C0-159B-44A6-8438-A5CE0A48CD90Q24186057-D1BE1C97-82ED-427D-8E34-F4D1459970ABQ24248715-B8550506-7AE5-47A8-A5D9-9511E238301FQ26752868-0D03838B-C7D9-408A-9BD8-ADE2E82CD0E9Q27009995-8409001F-A9A4-4699-9D27-C61685189173Q34183517-A1A0F86F-D5AA-4A03-A7C1-A82247863EFAQ34224290-FEC280B6-DBB2-43FD-A55A-817038E11D17Q34228150-72DFA221-769F-4BAC-93F9-118F7244015CQ34304950-3F1F57A9-1E88-4DCE-A8E7-E9F5C5D9BBCFQ34353112-6D1D3EA0-6086-41A1-AC66-4827B58DCC82Q34465555-8A902614-2D14-45E9-908C-3D535D1D1308Q34484276-4D30BAB8-69ED-4ECE-B121-DBAF6CF818D3Q34645876-03CBC56E-C2B2-46D6-9E72-33EC14F52012Q34662418-D57429B1-6C25-4097-9338-CF7F0C4A58AEQ34853281-38EDC3CE-F25F-43AE-8CE3-7E719FECC54FQ35006965-316EED7E-18B5-4B2F-8297-E03CE77F909DQ35062660-A62EAC9E-59F8-4EC1-AE9B-C50E30A8E5DEQ35666166-E247DF4B-4BA4-4AA4-AD45-8E3442D582CAQ35680402-76165DEC-545A-4608-968F-22A5BCF8F367Q35738679-FE46C497-E01F-45C1-B4C0-E54553EB5823Q35841600-F6E784BC-A4F1-4208-9E05-2E09A1EC2197Q36106955-27916B7E-9A11-4F7F-8C20-A08DD0274EB0Q36107118-663838C0-A826-44FA-AFD1-40BAE243FEB0Q36198579-5575E403-897C-4382-BE9C-4CEE5C0EACC8Q36366194-37674488-4553-4351-8252-E81FD9DA5A42Q36419538-6CAB1AC1-437B-484C-8B23-AB2FADE2538AQ36837462-60068F53-0911-4CA3-A0CD-B6CF25B69D43Q37041164-318643B7-359F-439D-985F-A868ACAAACDBQ37062590-9E30FF74-2C5B-4DB8-A004-6506A16D2D0CQ37086857-D1ACC933-F49C-443D-A050-FF1B4412D325Q37104120-DBFA3EB9-8CDE-4434-A779-13CC6C3CCA04Q37115879-7F90204E-1E37-4FE0-A8E3-6A282A927269Q37125514-24C161FF-372E-4FE3-8D93-34EAE9581AC3Q37164688-0919A9B2-A44F-4B8B-A8AD-20FB299B2446Q37219387-64084749-4C94-4F6B-98C6-7D2811D1DFA6Q37219391-5A1D853B-1D4E-4462-8CA3-BF8D666B64DFQ37224580-43B7A79B-3A2B-49B5-9B94-043A21CCBB14Q37610268-9DE7B774-B97B-40C0-AC39-5A9D91C28691Q37694597-04B7BA5A-F9A7-4BCD-A902-312E71CDA4DDQ38031324-B1602177-4B0F-487A-9143-BB696E7C1904
P2860
Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Efficacy of extended-release v ...... generalized anxiety disorder.
@en
Efficacy of extended-release v ...... generalized anxiety disorder.
@nl
type
label
Efficacy of extended-release v ...... generalized anxiety disorder.
@en
Efficacy of extended-release v ...... generalized anxiety disorder.
@nl
prefLabel
Efficacy of extended-release v ...... generalized anxiety disorder.
@en
Efficacy of extended-release v ...... generalized anxiety disorder.
@nl
P2093
P1476
Efficacy of extended-release v ...... h generalized anxiety disorder
@en
P2093
P304
P356
10.1176/APPI.AJP.157.6.968
P407
P577
2000-06-01T00:00:00Z